These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10997418)

  • 61. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
    Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nevirapine absorbed well despite chronic diarrhea.
    Weinberg WG
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):597. PubMed ID: 15989468
    [No Abstract]   [Full Text] [Related]  

  • 63. An open-label pilot study to determine the efficacy of lopinavir/ritonavir and tenofovir DF in the treatment of HIV-infected patients experiencing first virologic failure on a non-nucleoside-based regimen.
    Pierone G; Mieras J; Bulgin-Coleman D; Kantor C; Shearer J; Fontaine L; Fath M
    AIDS Patient Care STDS; 2008 Apr; 22(4):263-6. PubMed ID: 18422459
    [No Abstract]   [Full Text] [Related]  

  • 64. Summaries for patients. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and patient outcomes.
    Ann Intern Med; 2007 Apr; 146(8):I28. PubMed ID: 17438312
    [No Abstract]   [Full Text] [Related]  

  • 65. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Strategic selective treatment in highly pre-treated HIV patients harbouring multiply resistant viruses.
    Maggiolo F; Callegaro A; Gregis G; Quinzan G; Ripamonti D; Arici C; Goglio A; Suter F
    AIDS; 2002 Jan; 16(2):298-9. PubMed ID: 11807319
    [No Abstract]   [Full Text] [Related]  

  • 67. Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.
    Ross L; Johnson M; DeMasi R; Liao Q; Graham N; Shaefer M; St Clair M
    AIDS; 2000 May; 14(7):813-9. PubMed ID: 10839589
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combination therapies for HIV infection and genomic drug resistance.
    Katzenstein D
    Lancet; 1997 Oct; 350(9083):970-1. PubMed ID: 9329506
    [No Abstract]   [Full Text] [Related]  

  • 69. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
    Notermans DW; Jurriaans S; de Wolf F; Foudraine NA; de Jong JJ; Cavert W; Schuwirth CM; Kauffmann RH; Meenhorst PL; McDade H; Goodwin C; Leonard JM; Goudsmit J; Danner SA
    AIDS; 1998 Jan; 12(2):167-73. PubMed ID: 9468365
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen.
    Pellegrin I; Garrigue I; Caumont A; Pellegrin JL; Merel P; Schrive MH; Bonot P; Fleury H
    AIDS; 2001 May; 15(8):1071-3. PubMed ID: 11399996
    [No Abstract]   [Full Text] [Related]  

  • 71. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Substituting nevirapine for protease inhibitors because of intolerance.
    Dieleman JP; Gyssens IC; Sturkenboom MJ; Niesters HG; van der Ende ME
    AIDS; 1999 Jul; 13(11):1423-4. PubMed ID: 10449304
    [No Abstract]   [Full Text] [Related]  

  • 73. A comparison of three initial antiretroviral AIDS regimens.
    Ribaudo HJ; Kuritzkes DR; Gulick RM
    N Engl J Med; 2007 Sep; 357(10):1056-7. PubMed ID: 17804858
    [No Abstract]   [Full Text] [Related]  

  • 74. Severe hepatic failure related to nevirapine treatment.
    Cattelan AM; Erne E; Salatino A; Trevenzoli M; Carretta G; Meneghetti F; Cadrobbi P
    Clin Infect Dis; 1999 Aug; 29(2):455-6. PubMed ID: 10476768
    [No Abstract]   [Full Text] [Related]  

  • 75. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.
    Haubrich RH; Kemper CA; Hellmann NS; Keiser PH; Witt MD; Forthal DN; Leedom J; Leibowitz M; Whitcomb JM; Richman D; McCutchan JA;
    AIDS; 2002 Oct; 16(15):F33-40. PubMed ID: 12370520
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.
    Cassol E; Page T; Mosam A; Friedland G; Jack C; Lalloo U; Kopetka J; Patterson B; Esterhuizen T; Coovadia HM
    J Infect Dis; 2005 Feb; 191(3):324-32. PubMed ID: 15633090
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myelopathy in a previously asymptomatic HIV-1-infected patient.
    Eyer-Silva WA; Auto I; Pinto JF; Morais-de-Sá CA
    Infection; 2001; 29(2):99-102. PubMed ID: 11339484
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance.
    Muccini C; Spagnuolo V; Canetti D; Bigoloni A; Cernuschi M; Franzin M; Sampaolo M; Castagna A
    AIDS; 2020 Nov; 34(14):2152-2155. PubMed ID: 33105172
    [No Abstract]   [Full Text] [Related]  

  • 79. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.
    Clumeck N; Goebel F; Rozenbaum W; Gerstoft J; Staszewski S; Montaner J; Johnson M; Gazzard B; Stone C; Athisegaran R; Moore S;
    AIDS; 2001 Aug; 15(12):1517-26. PubMed ID: 11504984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.